Published in final edited form as:

Cell Mol Life Sci. 2013 May ; 70(10): 1779–1792. doi:10.1007/s00018-013-1312-6.

Interactions between VEGFR and Notch signaling pathways in endothelial and neural cells

Jean-Leon Thomas,

Department of Neurology, Yale University School of Medicine, New Haven, CT 06510-3221, USA. Université Pierre and Marie Curie–Paris 6, CRICM, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France. INSERM, UMRS 975, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France. APHP, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France

Kasey Baker,

Department of Cardiology, Yale University School of Medicine, New Haven, CT 06510-3221, USA

Jinah Han,

Department of Cardiology, Yale University School of Medicine, New Haven, CT 06510-3221, USA

Charles Calvo,

Université Pierre and Marie Curie–Paris 6, CRICM, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France. INSERM, UMRS 975, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France. APHP, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France

Harri Nurmi,

Wihuri Institute and Molecular Molecular/Cancer Biology Laboratory, Biomedicum Helsinki and Department of Pathology Haartman Institute, University of Helsinki, Helsinki, Finland

Anne C. Eichmann, and

Department of Cardiology, Yale University School of Medicine, New Haven, CT 06510-3221, USA. CNRS/UMR, Center for Interdisciplinary Research in Biology, 7241-INSERM U1050, Collège de France, 75005 Paris, France

Kari Alitalo

Wihuri Institute and Molecular Molecular/Cancer Biology Laboratory, Biomedicum Helsinki and Department of Pathology Haartman Institute, University of Helsinki, Helsinki, Finland

Jean-Leon Thomas: jean-leon.thomas@yale.edu

Abstract

Notch cell interaction mechanism governs cell fate decisions in many different cell contexts throughout the lifetime of all Metazoan species. It links the fate of one cell to that of its neighbors through cell-to-cell contacts, and binding of Notch receptors expressed on one cell to their membrane bound ligands on an adjacent cell. Environmental cues, such as growth factors and extracellular matrix molecules, superimpose a dynamic regulation on this canonical Notch signaling pathway. In this review, we will focus on Notch signaling in the vertebrate vascular and nervous systems and examine its role in angiogenesis, neurogenesis, and neurovascular interactions. We will also highlight the molecular relationships of the Notch pathway with vascular endothelial growth factors (VEGFs) and their high-affinity tyrosine kinase VEGF receptors, key regulators of both angiogenesis and neurogenesis.

Keywords

Angiogenesis; Neurogenesis; Neurovascular interactions; Notch; VEGFs; VEGFRs

Introduction

The vertebrate central nervous system (CNS) develops upon its colonization and irrigation by the vascular system. During embryonic development, the vessels provide trophic support and growth factors to proliferating and differentiating neural cells. In turn, neural cells provide cues to endothelial cells (ECs) for infiltration and expansion into the neural tissue [1, 2]. The close structural and functional relationship between the nervous and the vascular system persists in the adult brain. The importance of these interactions is apparent in maintenance of the remaining adult stem cell niches and in the dependence of injury responses triggered by trauma on cerebrovascular network properties [3].

The mutual interaction between neural and ECs is based on signaling molecules common to both cell types [4]. Notch is a major signaling pathway that regulates the development of many cell types, including endothelial and neural cells. It is one of the most well-conserved signaling pathways in multicellular organisms [5]. Notch has been shown to influence multiple cellular processes including: cell fate decisions, proliferation, apoptosis, migration, and plasticity. The canonical Notch pathway is initiated when Notch receptors expressed on one cell bind with their membrane-bound ligands on an adjacent cell, linking the fate of one cell to that of its neighbor [6–8]. In mammals, there are four Notch receptors (Notch1–4), which are single-pass transmembrane heterodimers, and five Notch ligands belonging to the Delta-Serrate-Lag (DSL) family, including Jagged1 and 2 (Jag1, Jag2) and Delta-like 1, 3, and 4 (Dll1, Dll3, Dll4) [9].

During angiogenesis, cell fate decisions among a group of ECs occur at the level of angiogenic sprouts, where ‘tip’ or leader cells segregate from the ‘stalks’ or trailing ECs forming the core of the vessel [10]. Tip cells localize at the very front of angiogenic sprouts and are characterized by extensive filopodia protrusions that sense guidance cues in the environment. Tip cells are also molecularly distinct from stalk cells, most notably by their high expression of Notch ligand Dll4 as well as VEGFR-2 [11, 12]. The role of Notch signaling in angiogenic sprouting has been demonstrated through genetic inactivation and/or pharmacological blocking of either Notch1 signaling or Dll4, which promotes tip cell formation and EC proliferation. Blocking the Notch pathway results in mispatterned angiogenic growth and the formation of a hyperplastic, immature, and nonfunctional vascular network [13–18]. Notch signaling is thus required for sprouting angiogenesis. Complex interactions between Notch and the VEGFRs, especially VEGFR-2 and VEGFR-3, have been shown to modulate Notch signaling and its effects on angiogenic activity [19–22].

Notch signaling also influences a wide array of cellular processes in the mammalian CNS and is essential during both embryonic and adult neurogenesis [6, 7]. Notch signaling mechanisms in neural cells are, however, far less understood than in ECs, most notably due to the difficulty in identifying ligand- and receptor-bearing cells within such a complexly structured tissue composed of such a wide diversity of cells. At early stages of CNS development, i.e., E11.5–E13.5 in the mouse, the embryonic neuroepithelium contains radial glia, neuronal progenitor cells, young neurons, as well as sprouting ECs, all of which establish Notch-mediated interactions. The neurogenic niches of the adult brain, the subventricular zone (SVZ) lining the lateral ventricles, and the subgranular zone (SGZ) of dentate gyrus (DG), are structured similarly, and are composed of the same types of cells, which also establish a highly complex network of Notch-mediated interactions. The first aim

of this review will be to discuss the relationship between Notch and the VEGFRs during angiogenesis. We will then review the role and mechanisms of Notch signaling during neurogenesis, and explore the possibility of Notch–VEGFR signaling pathway interactions during regulation of neural stem cell.

The Notch signaling pathway

The canonical Notch pathway involves the cell-surface Notch molecule, which successively plays the role of a receptor and a transcription factor [23, 24]. Ligand binding initiates a series of proteolytic cleavages of the Notch receptor, which culminates in cleavage of the transmembrane domain by gamma-secretase and the subsequent release of the Notch-intracellular domain (Notch ICD or NICD) into the cytosol. NICD translocates to the nucleus where it interacts with and converts the DNA-binding protein CBF1 (C promotor-binding factor, also known as RBPJk in mammals) complex into an activator complex. The NICD/CBF1 activator complex, which includes the coactivator Mastermind (MAML in mammals, [25]) among others [26], initiates the transcription of Notch target genes. Ubiquitous Notch target genes include the hairy and enhancer of split (HES) family genes and HES-related genes *Hesr1* and *Hesr2* (also known as *Hey*/*Herp* genes), which encode basic helix-loop-helix (bHLH) transcription factors that promote progenitor cell survival and suppress differentiation [27, 28].

In most biological situations, including in disease [29], the outcome of Notch signals depends on quantitative parameters [8]. The level of Notch target gene activation is intimately dependent on the ‘strength’ of the signal and Notch expressing cells display a dynamic response to temporal variations of Notch ligand expression on neighboring cells. Recent genetic and genomic approaches, moreover, showed that Notch signals can be attenuated by a large number of genes and that the above canonical pathway is integrated in a complex genetic circuitry with consequences on Notch signaling output [30–34]. Notch target genes can be regulated by other non-canonical Notch signaling pathways, which are independent of NICD, CSL, or even Notch receptor itself [9, 35], specifically, the VEGF-A/VEGFR-2 axis and its Notch independent-activation of Notch target genes in endothelial and neural cells, which we will discuss later. Consequently, despite the apparent simplicity of its canonical pathway, the Notch pathway is complexed with other pathways able to regulate and activate it. Therefore, a readout of Notch pathway target gene expression must be carefully interpreted and other steps in the pathway examined in order to properly identify Notch-dependent mechanisms.

VEGFs and VEGFRs

Vascular endothelial growth factor (VEGF or VEGF-A) strongly promotes angiogenesis and is required for vascular development [36, 37]. It binds the tyrosine kinase receptors VEGFR-1 (Flt1) and VEGFR-2 (Flk1), the latter being the primary receptor transmitting VEGF signals in ECs [38, 39].

VEGFR-1 binds VEGF-A with higher affinity than does VEGFR-2, but VEGFR-1 tyrosine kinase activity is only weakly activated by its ligands [40, 41], which makes that VEGFR-1, as well as its soluble form sVEGFR-1, acts as a VEGF decoy in ECs, regulating the spatial activation of VEGFR-2 and the formation of vascular sprouts [42]. VEGFR-2 is known to transduce the full range of VEGF-A responses in ECs, i.e., regulating EC survival, proliferation, migration, and formation of the vascular tube [41, 43].

VEGFR-3 is the third member of the VEGFR family and is expressed in the vascular system with a restriction to lymphatic ECs from stage E16.5 [44]. This receptor is activated by VEGF-C and VEGF-D. VEGF-C can also bind VEGFR-2 after proper proteolytic cleavage,

leading to the formation and activation of VEGFR-2/VEGFR-3 heterodimers [41, 45]. However, its highest binding affinity is for VEGFR-3 [46]. VEGFR-3 also regulates angiogenesis and *Vegfr3* deletion causes severe defects in arterial-venous remodeling of the primary vascular plexus in mice, with a lethality at stage E10.5 [47], and defective segmental artery morphogenesis in zebrafish [48]. VEGF-C/VEGFR-3 is most well known for its role in development of the lymphatic vascular network. VEGF-C acts as an attractive cue for lymphatic progenitor cells. Bi-allelic deletion of *Vegfc* in the mouse leads to a complete failure of lymphatic vessel formation and embryonic lethality at stage E16.5. Mice heterozygous for *Vegfc* can survive as adults, with lymphatic vessel hypoplasia and lymphedema, but no marked defects of the blood vasculature [49].

Interestingly, double *Vegfc*^{-/-}/*Vegfd*^{-/-} mutants survive until E16.5 and do not recapitulate the phenotype of *Vegfr3*^{-/-} mutants, suggesting VEGF-C/VEGF-D-independent activation of VEGFR-3. In support of this hypothesis, it was found that VEGFR-3 on cultured human dermal blood vascular ECs can be phosphorylated via stimulation by collagen-I in the absence of its ligands VEGF-C/VEGF-D, and even in the presence of blocking antibodies against VEGFR-3 [45]. This observation is in agreement with previous reports showing that a cooperative interaction between the $\beta 1$ -integrin and VEGFR-3 is required for EC endothelial cell migration [50] and that extracellular matrix induces integrin-mediated VEGFR-3 phosphorylation and downstream activation of CRKI/II—SHC (Src homology and collagen homology protein)—JNK cascade [51]. Therefore, VEGFR-3 mediates both ligand-dependent effects through an ‘active’ pathway and extra-cellular matrix-dependent effects through a ‘passive’ pathway which proved to be pro- and anti-angiogenic, respectively, as we will discuss later [19, 21, 52].

Notch and VEGFRs interactions during angiogenesis

Notch signaling is essential for vascular development. Notch-1 and Notch-4 receptors as well as JAG-1, Dll-1, and Dll-4 ligands are expressed in ECs where they play a key role in the induction of arterial cell fate and in sprouting angiogenesis [53]. The necessity of Dll-4/Notch-1 signaling in ECs was made apparent when deletion of Notch-1, or a single copy of Dll-4 resulted in severe vascular defects and embryonic lethality [54, 55]. In vascular sprouts, the tip cells express high levels of Notch ligand Dll4 and are Notch-1-deficient, while the trailing ECs, or stalk cells, as a result of their contact with the Dll4-expressing tip cells [14–18, 56]. Heterozygous deletion of Notch ligand Dll4 increases the number of filopodia and sprouting tips [17]. Similarly, blockade of Notch increases the number of filopodia and sprouting tips, with an associated expansion of VEGFR-3 (*Flt4*) expression [16, 57]. Tip cells with low Notch activity show high VEGFR-2 and low VEGFR-1 expression, indicative of an increase in VEGF-A signaling activity, as well as higher levels of Dll4 expression in tip cells [13, 15–17, 22, 58, 59]. In contrast, stalk cells have high levels of Notch signaling due to activation by the adjacent tip cells. Stalk cells, however, strongly express another Notch ligand, Jagged-1, which has a lower binding affinity for Notch compared to Dll4, but nevertheless can antagonize Dll4 activity by competing for Notch receptors. Modification of Notch by FRINGE glycosyltransferase favors activation by Dll4, but and reduces Notch activation upon Jagged-1 [60]. Consequently, the forward induction of Notch signaling is reduced in the vascular front which maintains EC responsiveness to VEGF stimulation, sustaining tip cell sprouting activity and also allowing new tip cells to form along the front to form branching vessels [61]. Vessel branching within the developing vascular network is also the consequence of another down-stream Notch target, Notch-regulated ankyrin-repeat protein (Nrarp), which counteracts Notch signaling and is expressed in stalk cells at the branch points [11].

Silencing of Nrarp results in a reduction in vessel density, due to lowered endothelial cell proliferation, a consequence of an up-regulation of Notch and VEGFR-1. The resulting vessels are also poorly lumenized and vessel regression can be seen in the network, a consequence of increased Wnt signaling, which Nrarp also balances in the stalk cells [11]. In this context, a balance is created by anti-angiogenic Dll4 and proangiogenic Jagged-1 to regulate Notch activation, the level of which determines its interactions with VEGF/VEGFR and other signaling pathways. All of this pathway cross-talk is essential for proper development and patterning of the vasculature as well as its stabilization [62].

A group of studies determined that VEGFR-3 also interacts with Notch to regulate sprouting angiogenesis. High levels of VEGFR-3 expression were detected in angiogenic sprouts and when VEGF-C/VEGFR-3 interactions were inhibited with function blocking anti-VEGFR-3 antibodies the authors saw decreased sprouting, vascular density, vessel branching, and endothelial cell proliferation in different mouse angiogenic models, both in vivo and in vitro. Conversely, they showed that VEGF-C-mediated stimulation of VEGFR-3 promoted angiogenesis, even in the presence of antibodies against VEGFR-2, and that a combination of blocking antibodies against VEGFR-2 and VEGFR-3 resulted in additive inhibition of angiogenesis and tumor growth [22]. Further investigations focused on VEGF-C-mediated VEGFR-3 revealed that *Vegfc* homozygous mutants displayed reduced vascular branching and that macrophages served as a source of VEGF-C ligand for the VEGFR-3⁺ tip cells localized at branching points [21]. In conjunction, the authors showed that the cell-type-specific deletion of *VEGFR-3* in ECs led to excessive angiogenic sprouting and branching, which was associated with a decreased level of Notch. *FoxC2*^{+/-}; *VEGFR-3*^{+/-} compound heterozygote mice were also examined and found to recapitulate homozygous deletion of *VEGFR-3*, implicating that VEGF-C binding to VEGFR-3 activates PI(3) K and its downstream target FoxC2, a known regulator of Notch ligand, Dll4, and target gene expression [21, 63]. This phenotype, contrasted with the suppressed angiogenesis induced by anti-VEGFR-3 blocking antibodies, revealing that the VEGFR-3 intracellular domain is endowed with signaling properties, independently of VEGF-C-activation of VEGFR-3 extracellular domain. The action of this domain moreover antagonizes the effect of VEGF-C stimulation. Using cultured human blood vascular ECs, the authors showed that VEGFR-3 could be phosphorylated, in absence of its ligands, through contact with extracellular matrix collagen I, and that VEGFR-3 activation was then Src-dependent. Together, these findings demonstrate the dual action of VEGFR-3 in angiogenesis, i.e., on the one hand, passive, ubiquitous and anti-angiogenic through interactions with the extracellular matrix and, on the other hand, active, local and pro-angiogenic following VEGFR-3 stimulation by its ligands VEGF-C and VEGF-D.

Subsequent studies focused on Notch-VEGFR-2 interactions during sprouting angiogenesis and showed that Dll4 can be highly expressed by ECs in the absence of VEGF-A/VEGFR-2 signaling, provided that ECs are without Notch signaling [19]. Although surprising with regards to the convergent observations reported above that VEGF-A induces the Notch ligand Dll4 in tip cells which leads to suppression of excess sprouts in adjacent ECs, this result indicates that Notch signaling regulates and determines the level of response of ECs to VEGF-A, as well as the prevalent expression of VEGFR-2 versus VEGFR-3 in ECs. The authors carried out cell-type-specific deletions of *Notch* and *RBPJk* in ECs (*Notch1*; *RBPJkiΔEC*), which strongly upregulated VEGFR-3 protein, without altering *VEGFR-2* expression, in ECs. This observation confirmed the potent inhibitory control of Notch signaling on VEGFR-3 expression, previously reported by Tammela et al. [22]. The *Notch1* *RBPJkiΔEC* mice showed a misoriented vascular growth and excessive sprouting which were not rescued by blocking antibodies against VEGFR-3, but instead by MAZ51, an inhibitor of VEGFR-3 tyrosine kinase activity. These results confirm that VEGFR-3 receptor acts independently of VEGF-C in ECs, as reported by Tammela et al. [21] and

suggests that ‘passive’ VEGFR-3 signaling can also promote angiogenic sprouting, provided that the ECs have little to no Notch activity. This led Benedito and Hellstrom [52] to propose that, while VEGFR-3 is normally an antagonist of sprouting, in this situation of minimal Notch activity, it may become an agonist. These elegant and complementary studies, which are summarized in Fig. 1a, demonstrate the highly dynamic balance of Notch and VEGFR-2/VEGFR-3 expression in ECs, as well as the highly versatile role of VEGFR-3 in angiogenesis.

Angiogenesis is not a continuous process and recent reports showed that in the developing zebrafish circadian oscillations control developmental angiogenesis. It was found that the circadian regulator *Bmal1* directly targets the promoter region of the *Vegf* gene leading to an elevated expression of VEGF-A [64, 65]. These data confirm previous reports in mice of the circadian expression of VEGF-A in murine tumor cells [66]. Interestingly, Notch signaling is also regulated in an oscillatory fashion and the gene *Hes7*, which is regulated by the Notch and Fgf/Mapk pathways is a crucial component of the segmentation clock [67, 68]. The Notch-VEGF-A interactions in the oscillatory regulation of angiogenesis have, however, not yet been explored.

Notch signaling in neurogenesis

The embryonic phenotype associated with the haploinsufficiency of the Notch locus was one of the first genetic mutation characterized in the fly (*Drosophila melanogaster*) [69]. It was described as a ‘neurogenic phenotype’ resulting from the failure of the neurogenic ectoderm to segregate neural and epidermal cell lineages. All cells become neuroblasts, which causes hypertrophy of neural tissue at the expense of epidermal structures. In the mouse, targeted mutation of the Notch pathway genes *Notch1* and *RBPJk* also implicated a role for these genes in neurogenesis implicating that the Notch pathway and its regulatory mechanisms were conserved from fly to mouse [70]. *Notch1* and *RBPJk* mutations led to decreased expression of the Notch target gene *Hes-5* and upregulation of proneural gene *Mash-1* and Notch ligand *Dll1*, resulting in enhanced neurogenesis. Interestingly, no change in *Hes-1* expression were detected in these mutants, suggesting that *Hes-1* expression during early embryonic neurogenesis is not, or not mainly, controlled by the canonical Notch pathway. The *RBPJk* mutation showed stronger effects on proneural gene expression than the *Notch1* mutation, consistent with functional redundancy of Notch genes in neurogenesis. These findings supported a role for Notch signaling in the regulation of neural stem cell differentiation, but the early lethality of *Notch1* mutants (E11.5) did not allow assessment of the long term consequences of deletion on the neural stem cell pool. To circumvent this difficulty, several studies have used Cre/loxP-mediated recombination to remove *Notch1* in subsets of neural cells [71–73]. Interestingly, the telencephalic deletion of *Notch* led to a reduced neuron number in vivo later in development, confirming expectations of the effects of progressive depletion of neural progenitor pool [72]. Neurosphere assays from single embryonic neural stem cells derived from mice deficient for *Notch1*, *RBPJk* or *Presenilin1*, another key regulator in Notch signaling, were used to support in vivo results in *RBPJk*^{-/-} or *Notch1*^{-/-} embryonic mice and in the adult *PS1*^{+/-} mutants all of which revealed a neural stem cell depletion [74]. Interestingly, these authors also found that *RBPJk* and Notch signaling were, however, dispensable for generation of neural stem cells from embryonic stem cells.

In the adult brain, Notch signaling pathway molecules are expressed in both the SVZ and SGZ [75–79]. Converging pharmacological and genetic evidence indicate that the canonical Notch pathway regulates maintenance of adult NSCs through promotion of their self-renewal and inhibition of their exit from the cell cycle, as well as regulating generation of neuronal and glial precursor cells within the regions. The SGZ of adult inducible *Notch*-

deficient mice displays an increased cell cycle exit of early precursor types [75], an impaired expansion of the progenitor pool [80] and a depleted stem cell population [77]. Conditional inactivation of *RBPJk* resulted in an initial increase in DG neurogenesis, by inducing premature neuronal differentiation of the pool of Sox2-positive neural stem cells depleting them, eventually leading to repression of adult hippocampal neurogenesis [81]. Conditional deletion of *RBPJk* in the Nestin-expressing stem cells had a similar effect in the adult SVZ. The type B stem cells within the region differentiated into transit-amplifying cells and neurons, depleting the neural stem cell pool resulting in premature cessation of neurogenesis [77]. Treatment of neural stem cells in vitro with the Notch inhibitor DAPT inhibited the cell cycle and extended the G1-S transition, allowing the cell to exit the cell cycle when levels of Notch signaling remain low [82]. Conditional genetics combined with mosaic analysis of Notch mutants showed that, in the adult SVZ, active neural stem cells display a selective reliance on Notch signaling, while Notch1 function is compensated in quiescent neural stem cells [83].

The group of Kageyama [84, 85] made an interesting observation that the level of Notch signaling in neural stem cells regulates the balance between quiescence and proliferation, the high Notch activation inducing growth arrest while low Notch signaling causes cell proliferation. This balance results from a constitutive oscillation of expression of the downstream Notch effector Hes1, with a period of 2–3 h by negative feedback. Consequently, Hes1 oscillations induce the oscillatory expression of the proneural gene Neurogenin2 (Ngn2) and the Notch ligand gene Delta-like1 (Dll1). Dll1 oscillation maintains a group of cells in the undifferentiated state while the different dynamics of Hes1 and Ngn2 lead to different outcomes. Hes1 allows cell proliferation and differentiation when its expression oscillates but induces dormancy when its expression is sustained. Ngn2 leads to the maintenance of neural stem/progenitor cells by inducing Dll1 oscillation when its expression oscillates but to neuronal differentiation when its expression is sustained. It is worth noting that, in contrast with neural stem cells, neuroblasts are less dependent on Notch and more responsive to environmental cues for regulation of their proliferation [80], which confirms the cell-type dependent effect of Notch signaling in neurogenesis. In addition to HES genes, EphB2 has been reported as a downstream mediator of Notch signaling which prevents differentiation of ependymal cells into niche astrocytes in the adult SVZ [86].

Regarding the upstream regulators of Notch signaling, several growth factors have been implicated. Interaction between EGF receptor signaling and Notch is required for maintenance of neural stem and progenitor cells in the adult SVZ. EGF receptor signaling in transit-amplifying type C cells non-cell-autonomously suppresses Notch signaling in type B cells and consequently inhibits their proliferation and self-renewal. This action results from Notch 1 ubiquitination and degradation via induction of Numb [87]. FGF signaling is also regulating Notch-dependent neurogenesis, with consequences on the expansion of embryonic cortical surface area, as shown by changes in the expression of Notch pathway genes in *FgfR* mutant embryos [88]. Several evidence have also been provided that Wnt signaling regulated embryonic neurogenesis upstream of Notch, in the hindbrain, cortex and retina [89–91]. SFRPs, which are Wnt signaling antagonists, also play an important role for Notch activation in the retina where Notch signaling was transiently upregulated in *Sfrp1*^{−/−}; *Sfrp2*^{−/−} embryos, because SFRPs bind ADAM10 metalloprotease and downregulate Notch activity [92]. Sonic Hedgehog (SHH) morphogen is another upstream regulator of Notch signaling as shown for embryonic retinal progenitors ([93]; see next paragraph) and cortical progenitors. Conditional inactivation of *Patched1*, a negative regulator of the SHH pathway, in Nestin-positive neural progenitors of the neocortex led to an increase in the number of symmetric proliferative divisions of radial glial with a concomitant upregulation of *Hes1* and *Blbp*, downstream targets of Notch signaling [94]. Finally, a role for the Slit1/2-Robo1/2 axis, which is known as a regulator of axonal and EC guidance, has also been

shown in embryonic cortical progenitor cells where it activates transcription of the Notch effector *Hes1*, independently of Notch. Proliferation of radial glial stem cells is inhibited while production of intermediate progenitors is enhanced in *Robo1/2* and *Slit1/2* mutants, suggesting that Slit/Robo signaling modulates the transition between primary and intermediate progenitors [95]. Together, these regulators may modulate ‘strength’ of Notch signaling directly through interactions with the pathway components or indirectly by targeting the same genes Notch does.

One key question that still remains is which cell types act as the main Notch ligand-presenting cell for these NSCs in the developing neuroepithelium and in the neurogenic niches of the adult brain. During development, ECs are in intimate contact with radial glia which have been shown to regulate vessel stabilization via modulation of canonical Wnt signaling in the late embryonic cortex [96]. In the adult subventricular zone, neural stem cells are also closely apposed to local blood vessels, and able to directly contact ECs due to decreased pericyte coverage [97, 98]. Since the two Notch ligands *Dll4* and *Jag1* are highly expressed by ECs [99], this opens possibility that ECs may also be Notch-ligand-presenting cells for embryonic and adult neural stem cells (Fig. 1b).

VEGFs and VEGFRs in neurogenesis

An increasing body of evidence shows that VEGF-A and its tyrosine kinase receptors also regulate development of the nervous system. In small invertebrates such as nematodes, which lack a vascular system and distribute oxygen by diffusion, orthologues of tyrosine kinase VEGF receptors are expressed by the nervous system and regulate neuronal and glial cell development [100, 101]. In vertebrates, all of the VEGFs and VEGF receptors are also expressed in the CNS throughout development [102]. Their instructive role for neural cell development and their implication in brain diseases and repair have been discussed elsewhere [103–106].

VEGF transcript levels are abundant in the ventricular neuroepithelium of embryonic brain when neural stem/progenitors cells and ECs proliferate rapidly [107]. This temporal and spatial expression of VEGF suggests that VEGF is synthesized and released by the ventricular neuroectoderm and that it may simultaneously induce the ingrowth of capillaries from the perineural vascular plexus and regulate neurogenic activity [108]. This is supported by findings that VEGF can act as a neurotrophic factor and as guidance cue for neural progenitors [109, 110]. Recently, *in vitro* studies using co-cultures of EC and neonatal rat brain slices suggested that VEGF-A is the main neurogenic factor delivered by ECs since RNA interference against VEGF-A strongly inhibited the proliferation of Nestin⁺ neural progenitors in the presence of ECs [111]. Interestingly, VEGF-A depletion also altered expression of *Pten*, *Akt1*, and *PI3P* genes encoding key regulators of VEGFR signaling pathway [41].

Although VEGF-A proved to be a strongly neurogenic factor, its direct action has only been demonstrated for subsets of neural progenitor cells, as indicated above. It has not been established if this local effect was linked to a region-specific pattern of expression and if other members of VEGF family had eventually a complementary expression pattern and may substitute to VEGF-A for regulating neurogenesis. VEGFR-2 expression is also restricted to subpopulations of neural cells, mostly neurons [112, 113], suggesting that VEGF-A may not preferentially target neural stem cells but rather neuronal progenitors or neuroblasts. We have recently provided evidence that the lymphangiogenic ligand VEGF-C and its high-affinity receptor VEGFR-3 also regulated neurogenesis by acting on neural stem cells and niche astrocytes, thus with a distinct cell-type specificity than the VEGF-A/VEGFR-2 axis.

VEGF-C, VEGF-D, and VEGFR-3 are expressed at low level by blood ECs endothelial cells and by other cell types, including neural cells [114]. In contrast to VEGF-A and VEGFR-2, which show a restricted spatio-temporal expression pattern in the CNS [4, 115, 116], VEGFR-3- and VEGF-C-expressing cells have a broad and complex distribution in the developing and adult brain. As illustrated in Fig. 2, VEGF-A and VEGF-C show different patterns of expression in the developing brain. VEGF-A is highly expressed in ECs while VEGF-C expression is rather restricted to radial glia, in specific domains of the ventricular zone. Using *Vegfc^{lacZ}+* and *Vegfr3^{lacZ}+* mice to detect β -galactosidase reporter expression of *Vegfc* and *Vegfr3* respectively, as well as antibodies to stain VEGF-C and VEGFR-3, we have described overlapping or adjacent expressing patterns of VEGF-C and VEGFR-3 in different territories of the embryonic forebrain, midbrain and hindbrain, suggesting functional ligand/receptor interactions between VEGF-C and VEGFR-3 [117]. VEGF-C/VEGFR-3 are especially coexpressed in proliferative neuroepithelial domains of the ventral forebrain, such as the preoptic region and the olfactory bulb anlage, where proliferation of neural progenitors and migration of oligodendrocyte precursors was altered in both *Vegfc^{lacZ}+* and *Vegfc^{lacZ}lacZ⁻*-deficient embryos. Additional loss-of function mutations in *Xenopus* confirmed the specific requirement of VEGF-C for the proliferation of neural progenitor cells expressing VEGFR-3. Therefore, VEGF-C provides a trophic support to neural progenitor cells during vertebrate brain development.

VEGF-C and *Vegfr3* expression in the embryonic and postnatal brain was characterized in detail in rats, using a combination of in situ hybridization, RT-PCR and immunolabeling analyses which confirmed overlapping cerebral expression of *Vegfr3* and *Vegfc*, notably in the hippocampus of control and ischemic animals [118–121]. These studies showed a specific VEGFR-3 expression in radial glial cells of the embryonic forebrain as well as in adult SVZ cells, suggesting that VEGFR-3 may contribute to forebrain neurogenesis during the lifespan. Interestingly, VEGFR-3 expression persisted in adult radial glia including tanycytes of third ventricle, retinal Muller cells and cerebellar Bergmann glia, which display neural stem cell properties in vitro [118]. We have recently addressed the role of VEGFR-3 in adult neurogenesis, first focusing on the SVZ [122]. Using transgenic BAC *VEGFR-3::YFP* mice to visualize and isolate living *Vegfr3*-expressing cells, we found that adult SVZ *VEGFR-3::YFP⁺* cells were predominantly (around 90 %) quiescent astrocytes and neural stem cells (Fig. 3a). Using the Cre/loxP system and a loxP-flanked (floxed) *Vegfr3* allele (*Vegfr3^{lox/lox}*) [123] to generate inducible cell-type-specific deletions of *Vegfr3* in neural cells, with a *Brn4Cre* driver line, or in astroglial cells, with a *GlastCreERT2* inducible driver line, we also showed that VEGFR-3 expression by SVZ astrocytes was required for proper adult neurogenesis and that VEGFR-3 mediated the promoting effect of VEGF-C on adult neurogenesis.

The dentate gyrus (DG) of the hippocampal formation is the second neurogenic niche of the adult brain, playing an important role in learning, memory, and mood regulation [124–126]. We have investigated recently *Vegfr-3* expression and role in DG neurogenesis and found that SGZ VEGFR-3⁺ cells were GFAP⁺ astrocytes and radial glia/stem cells as well amplifying progenitors (Fig. 3b). *Vegfr3* expression was not detectable in immature neurons and granule cells. Additional neurosphere assays performed on FACS-sorted *Vegfr3*-expressing cells from the DG of *Vegfr3::YFP* mice showed self-renewal and multipotency of these cells (data not shown; Calvo and Han, unpublished results). VEGFR-3 expression is therefore a hallmark of adult neural stem cells in the mouse. These findings suggest VEGFR-3 action in DG neurogenesis and raise the question of the nature of VEGFR-3 ligand, which may be VEGF-C or/and VEGF-D, because both are expressed in the DG [117, 121, 127]. They also lead to explore whether VEGFR-3 signaling in SGZ stem cells may mediate the effects of environmental changes, such as physical activity or stress, on DG neurogenesis and eventually modulate hippocampus-dependent behaviors.

Notch and VEGFRs interactions during neurogenesis

Evidence that VEGF and Notch signaling regulates neurovascular interactions resulted from pioneer works of Sally Temple's group [128]. In this study, the authors showed that endothelial coculture stimulated embryonic and adult neural stem cells by promoting their self-renewal, inhibiting their differentiation, and enhancing their neuron production. This effect resulted from the delivery of soluble factors from EC, and not vascular smooth muscle cells. Moreover, neuroepithelial and ECs established cell-to-cell contacts activating Notch and Hes 1 in neural stem cells to promote their self-renewal. Additionally, gene-chip analysis of EC-stimulated rat brain slices indicated that VEGF-A siRNA strongly altered expression of Notch2 and Hes1 transcripts, suggesting that VEGF-A modulates Notch signaling pathway induced by contact between neural cells or between neural cells and ECs [111]. Associative evidence of a link between VEGF-A, Notch activation and neurogenic activity was also provided for neonatal SVZ neural stem cells, where an enriched expression of both VEGF-A and cleaved notch-1 was found in the CD-1 mouse strain, which displays a robust neurogenic response to neonatal hypoxic insult, compared to C57BL/6 mice, which are less responsive and recover poorly from hypoxia [62].

Proof of a relationship between VEGF-A/VEGFR-2 and the Notch signaling pathway during neurogenesis was directly demonstrated early neuronal progenitors of the developing retina [129]. Using the model of the chicken retina, which is completely devoid of blood vessels throughout development [130], the authors showed that perturbing VEGF signals, as well as VEGFR-2 receptor function, during early stages of retinal neurogenesis influenced retinal progenitor cell proliferation and commitment. Augmenting VEGF signals increased progenitor cell proliferation and decreased retinal ganglion cell genesis. Conversely, absorbing endogenous VEGF ligand or disrupting VEGFR-2 activity attenuated cell proliferation and enhanced retinal ganglion cell production. VEGF signals transmitted by VEGFR-2 appeared to activate divergent intracellular signaling components, which regulate different responses of progenitor cells. VEGF-induced proliferation is influenced by the MEK-ERK pathway, as well as by the basic helix-loop-helix factor HES1. By contrast, VEGF-dependent ganglion cell suppression does not require MEK-ERK activation, but instead relies on VEGF-stimulated Hes1 activity, which is notably independent of Notch signaling. Based on their findings, the authors proposed that Hes1 is a signaling hub in early retinal progenitor cells to integrate various cell-extrinsic cues, including VEGF and also SHH, in order to control cell proliferation and neuronal specification (Fig. 1b).

To explore whether VEGFR-3 and Notch pathways interact to regulate neural stem cell maintenance in adult neurovascular niches, we performed microarray analysis of *Vegfr3::YFP*/CD31⁺ FACS-sorted cells (NSC and not EC) from the adult SVZ and showed that *Vegfr3* transcripts were coexpressed with high level of *Notch1* and Notch target gene (*Hes5*, *Hes1*) RNAs, compared to other niche cell types (Table 1). VEGF-C stimulation of SVZ niche cells moreover strongly increased expression of *Notch1*, *Hes5* and *Hes1* transcripts (data not shown). Further experiments testing in vivo the effects of Notch activation or blocking on VEGFR-3 activation, and of VEGF-C on Notch activity will determine whether VEGF-C and VEGFR-3 regulate and reinforce Notch signaling in adult SVZ NSCs, alike VEGF-A/VEGFR-2 in embryonic retinal progenitor cells.

Concluding remarks

The findings reported above indicate that proper growth of blood vessels requires a dynamic interaction between VEGFR-2, VEGFR-3 and Notch signaling pathways. Notch appears to regulate the relative importance of VEGFR-2 and VEGFR-3 for angiogenesis. Moreover, VEGFR-2 and Notch both modulate VEGFR-3 expression, independently and in opposite

directions. Consequently, while VEGFR-2 signaling is active and key regulator in ECs with high Notch activity and low VEGFR-3 expression, VEGFR-3 drives growth of ECs with low Notch signaling activity, even in the absence of VEGF ligands and VEGFR-2 signaling. In addition, VEGFR-3 can promote the stabilization of tip cells at vessel fusion sites by reinforcing Notch signaling through macrophage-derived VEGF-C activation. VEGFR-3 seems thus to have a dual pro-(active) and anti-(passive) angiogenic function and to complement the angiogenic action of VEGFR-2 in environmental context inappropriate for the VEGF-A/VEGFR-2 axis.

These findings now lead us to investigate the distinct signaling cascades activated by varying Notch activity in ECs. They also raise questions about the mechanisms that allow ECs to change frequently from a tip to a stalk position and to regulate Notch-VEGFRs interactions in a highly dynamic manner, likely by involving post-transcriptional regulations that have not yet been characterized. The highly dynamic Notch activity in ECs correlates with their ability to rapidly switch between tip and stalk cell fates during sprouting angiogenesis. Although neurogenesis does not always happen quite so rapidly, these signaling studies in angiogenesis offer a unique model for interpreting Notch-VEGFRs interaction in other cell types, including NSCs and their dynamic plasticity through development. Both VEGFR-2 and VEGFR-3 are expressed by different neural cell types and have already been implicated in various parts of neurogenic regulation. Interplay between Notch-VEGFR-2-VEGFR-3, as in ECs and angiogenic sprouts, may thus occur between different cell types within the neurogenic niches. These interactions may vary according to CNS region, developmental stages, and, or the cell types interacting to elicit regulation over a wider variety of processes and cell types in these complex tissues. For example, VEGF-A-VEGFR-2-Hes1 regulation may be prevalent in neuronal progenitors of the embryonic retina, whereas VEGF-C-VEGFR-3-Notch signaling governs astroglial/stem cell activity in the adult niches. Pharmacological approaches and genetic models are now available, allowing us to manipulate VEGFRs or Notch signaling molecules in these cell-type and spatio-temporal-specific patterns. Their combination will provide a better understanding of the neurogenic niche cells and will help us determine the diversity and the extent of regulation these pathways have on brain development and adult neurogenesis. These findings will set the groundwork for developing new therapies and improving current treatments for neural diseases, traumatic injuries, and age-related decline in humans.

Acknowledgments

This work was supported by Yale University School of Medicine (JLT, AE), NIH RO1HL111504-02 (AE, JLT, JH, KB), ANR blanc Neuroscience 2010 (JLT), Academy of Finland (KI, HN). We are indebted to Abdelkrim Mannioui and Hatem Hmidan for technical assistance.

References

1. Bautch VL, James JM. Neurovascular development: the beginning of a beautiful friendship. *Cell Adhesion Migr.* 2009; 3(2):199–204.
2. Ruhrberg C, Bautch VL. Neurovascular development and links to disease. *Cell Mol Life Sci.* 2013 (CMLS this issue).
3. Greenberg DA, Jin K. Vascular endothelial growth factors (VEGFs) and stroke. *Cell Mol Life Sci.* 2013 (CMLS this issue).
4. Carmeliet P, Ruiz de Almodovar C. VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration. *Cell Mol Life Sci.* 2013 (CMLS this issue).
5. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. *Science.* 1999; 284(5415):770–776. [PubMed: 10221902]
6. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. *Nat Rev Neurosci.* 2006; 7(2):93–102. [PubMed: 16429119]

7. Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: insights from mouse mutants. *Nat Neurosci.* 2005; 8(6):709–715. [PubMed: 15917835]
8. Artavanis-Tsakonas S, Muskavitch MA. Notch: the past, the present, and the future. *Curr Top Dev Biol.* 2010; 92:1–29. [PubMed: 20816391]
9. D'Souza B, Meloty-Kapella L, Weinmaster G. Canonical and non-canonical Notch ligands. *Curr Top Dev Biol.* 2010; 92:73–129. [PubMed: 20816393]
10. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J Cell Biol.* 2003; 161(6):1163–1177. [PubMed: 12810700]
11. Phng LK, Potente M, Leslie JD, Babbage J, Nyqvist D, Lobov I, Ondr JK, Rao S, Lang RA, Thurston G, Gerhardt H. Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. *Dev Cell.* 2009; 16(1):70–82. [PubMed: 19154719]
12. del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, Breant C, Duarte A, Takakura N, Fukamizu A, Penninger J, Eichmann A. Identification and functional analysis of endothelial tip cell-enriched genes. *Blood.* 2010; 116(19):4025–4033. [PubMed: 20705756]
13. Hellstrom M, Phng LK, Gerhardt H. VEGF and Notch signaling: the yin and yang of angiogenic sprouting. *Cell Adhesion Migr.* 2007; 1(3):133–136.
14. Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL, Lewis J. Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. *Development.* 2007; 134(5): 839–844. [PubMed: 17251261]
15. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegand SJ. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. *Proc Natl Acad Sci USA.* 2007; 104(9):3219–3224. [PubMed: 17296940]
16. Siekmann AF, Lawson ND. Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. *Nature.* 2007; 445(7129):781–784. [PubMed: 17259972]
17. Suchting S, Freitas C, le Noble F, Benedito R, Breant C, Duarte A, Eichmann A. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. *Proc Natl Acad Sci USA.* 2007; 104(9):3225–3230. [PubMed: 17296941]
18. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A, Gill PS. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. *Blood.* 2007; 109(11):4753–4760. [PubMed: 17311993]
19. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, Duarte A, Pytowski B, Adams RH. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. *Nature.* 2012; 484(7392):110–114. [PubMed: 22426001]
20. Hogan BM, Herpers R, Witte M, Helotera H, Alitalo K, Duckers HJ, Schulte-Merker S. Vegfc/Flt4 signalling is suppressed by Dll4 in developing zebrafish intersegmental arteries. *Development.* 2009; 136(23):4001–4009. [PubMed: 19906867]
21. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomaki A, Aranda E, Miura N, Ylä-Herttuala S, Fruttiger M, Makinen T, Eichmann A, Pollard JW, Gerhardt H, Alitalo K. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. *Nat Cell Biol.* 2011; 13(10):1202–1213. [PubMed: 21909098]
22. Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M, Hellström M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Ylä-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. *Nature.* 2008; 454(7204):656–660.10.1038/nature07083 [PubMed: 18594512]
23. Andersson ER, Sandberg R, Lendahl U. Notch signaling: simplicity in design, versatility in function. *Development.* 2011; 138(17):3593–3612. [PubMed: 21828089]
24. Bray S, Bernard F. Notch targets and their regulation. *Curr Top Dev Biol.* 2010; 92:253–275. [PubMed: 20816398]
25. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of *Drosophila* mastermind, is a transcriptional co-activator for NOTCH receptors. *Nat Genet.* 2000; 26(4):484–489. [PubMed: 11101851]

26. Fryer CJ, White JB, Jones KA. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. *Mol Cell*. 2004; 16(4):509–520. [PubMed: 15546612]
27. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. *J Cell Physiol*. 2003; 194(3):237–255. [PubMed: 12548545]
28. Kageyama R, Ohtsuka T. The Notch-Hes pathway in mammalian neural development. *Cell Res*. 1999; 9(3):179–188. [PubMed: 10520600]
29. Mazzone M. Novel alternatives for anti-angiogenetic therapy and therapeutic angiogenesis. *Verhandelingen Koninklijke Academie voor Geneeskunde van België*. 2010; 72(3–4):165–175. [PubMed: 21067068]
30. Hurlbut GD, Kankel MW, Lake RJ, Artavanis-Tsakonas S. Crossing paths with Notch in the hyper-network. *Curr Opin Cell Biol*. 2007; 19(2):166–175. [PubMed: 17317139]
31. Kankel MW, Hurlbut GD, Upadhyay G, Yajnik V, Yedvobnick B, Artavanis-Tsakonas S. Investigating the genetic circuitry of mastermind in *Drosophila*, a notch signal effector. *Genetics*. 2007; 177(4):2493–2505. [PubMed: 18073442]
32. Louvi A, Artavanis-Tsakonas S. Notch and disease: a growing field. *Semin Cell Dev Biol*. 2012; 23(4):473–480. [PubMed: 22373641]
33. Peter IS, Davidson EH. A gene regulatory network controlling the embryonic specification of endoderm. *Nature*. 2011; 474(7353):635–639. [PubMed: 21623371]
34. Saj A, Arziman Z, Stempfle D, van Belle W, Sauder U, Horn T, Durrenberger M, Paro R, Boutros M, Merdes G. A combined ex vivo and in vivo RNAi screen for notch regulators in *Drosophila* reveals an extensive notch interaction network. *Dev Cell*. 2010; 18(5):862–876. [PubMed: 20493818]
35. Heitzler P. Biodiversity and noncanonical Notch signaling. *Curr Top Dev Biol*. 2010; 92:457–481. [PubMed: 20816404]
36. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature*. 1996; 380(6573):439–442. [PubMed: 8602242]
37. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoek A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature*. 1996; 380(6573):435–439. [PubMed: 8602241]
38. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. *J Biol Chem*. 2001; 276(5):3222–3230. [PubMed: 11058584]
39. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature*. 1995; 376(6535):62–66. [PubMed: 7596435]
40. Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. *J Biol Chem*. 1998; 273(47):31283–31288. [PubMed: 9813036]
41. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. *Cold Spring Harbor Perspect Med*. 2012; 2(7):a006502.
42. Kappas NC, Zeng G, Chappell JC, Kearney JB, Hazarika S, Kallianos KG, Patterson C, Annex BH, Bautch VL. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. *J Cell Biol*. 2008; 181(5):847–858. [PubMed: 18504303]
43. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med*. 2003; 9(6):669–676. [PubMed: 12778165]
44. Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. *Development*. 1996; 122(12):3829–3837. [PubMed: 9012504]
45. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. *Cell*. 2010; 140(4):460–476. [PubMed: 20178740]

46. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. *EMBO J.* 1996; 15(7):1751. [PubMed: 8612600]
47. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. *Science.* 1998; 282(5390): 946–949. [PubMed: 9794766]
48. Covassin L, Amigo JD, Suzuki K, Teplyuk V, Straubhaar J, Lawson ND. Global analysis of hematopoietic and vascular endothelial gene expression by tissue specific microarray profiling in zebrafish. *Dev Biol.* 2006; 299(2):551–562. [PubMed: 16999953]
49. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. *Nat Immunol.* 2004; 5(1):74–80. [PubMed: 14634646]
50. Wang JF, Zhang XF, Groopman JE. Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration. *J Biol Chem.* 2001; 276(45):41950–41957. [PubMed: 11553610]
51. Galvagni F, Pennacchini S, Salameh A, Rocchigiani M, Neri F, Orlandini M, Petraglia F, Gotta S, Sardone GL, Matteucci G, Terstappen GC, Oliviero S. Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity. *Circ Res.* 2010; 106(12):1839–1848. [PubMed: 20431062]
52. Benedito R, Hellstrom M. Notch as a hub for signaling in angiogenesis. *Exp Cell Res.* 2013
53. Kume T. Novel insights into the differential functions of Notch ligands in vascular formation. *J Angiogenesis Res.* 2009; 1:8. [PubMed: 20016694]
54. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G, Yancopoulos GD. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. *Proc Natl Acad Sci USA.* 2004; 101(45):15949–15954. [PubMed: 15520367]
55. Limbourg FP, Takeshita K, Radtke F, Bronson RT, Chin MT, Liao JK. Essential role of endothelial Notch1 in angiogenesis. *Circulation.* 2005; 111(14):1826–1832. [PubMed: 15809373]
56. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalen M, Gerhardt H, Betsholtz C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. *Nature.* 2007; 445(7129):776–780. [PubMed: 17259973]
57. Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. *Nat Rev Cancer.* 2007; 7(5):327–331. [PubMed: 17457300]
58. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM, Rosewell I, Busse M, Thurston G, Medvinsky A, Schulte-Merker S, Gerhardt H. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. *Nat Cell Biol.* 2010; 12(10):943–953.10.1038/ncb2103 [PubMed: 20871601]
59. Sainson RC, Aoto J, Nakatsu MN, Holderfield M, Conn E, Koller E, Hughes CC. Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. *FASEB J.* 2005; 19(8):1027–1029. [PubMed: 15774577]
60. Eilken HM, Adams RH. Turning on the angiogenic microswitch. *Nat Med.* 2010; 16(8):853–854. [PubMed: 20689545]
61. Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M, Adams RH. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. *Cell.* 2009; 137(6):1124–1135. [PubMed: 19524514]
62. Li Q, Michaud M, Canosa S, Kuo A, Madri JA. GSK-3beta: a signaling pathway node modulating neural stem cell and endothelial cell interactions. *Angiogenesis.* 2011; 14(2):173–185. [PubMed: 21253820]
63. Hayashi H, Kume T. Foxc2 transcription factor as a regulator of angiogenesis via induction of integrin beta3 expression. *Cell Adhesion Migr.* 2009; 3(1):24–26.

64. Jensen LD, Cao Y. Clock controls angiogenesis. *Cell Cycle*. 2013; 12(3):405–408. [PubMed: 23324349]
65. Jensen LD, Cao Z, Nakamura M, Yang Y, Brautigam L, Andersson P, Zhang Y, Wahlberg E, Lanne T, Hosaka K, Cao Y. Opposing effects of circadian clock genes *bmal1* and *period2* in regulation of VEGF-dependent angiogenesis in developing zebrafish. *Cell Rep*. 2012; 2(2):231–241. [PubMed: 22884368]
66. Koyanagi S, Kuramoto Y, Nakagawa H, Aramaki H, Ohdo S, Soeda S, Shimeno H. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. *Cancer Res*. 2003; 63(21):7277–7283. [PubMed: 14612524]
67. Kageyama R, Niwa Y, Shimojo H. Rhythmic gene expression in somite formation and neural development. *Mol Cells*. 2009; 27(5):497–502. [PubMed: 19466597]
68. Oates AC, Morelli LG, Ares S. Patterning embryos with oscillations: structure, function and dynamics of the vertebrate segmentation clock. *Development*. 2012; 139(4):625–639. [PubMed: 22274695]
69. Poulson DF. Chromosomal deficiencies and the embryonic development of *Drosophila Melanogaster*. *Proc Natl Acad Sci USA*. 1937; 23(3):133–137. [PubMed: 16588136]
70. de la Pompa JL, Wakeham A, Correia KM, Samper E, Brown S, Aguilera RJ, Nakano T, Honjo T, Mak TW, Rossant J, Conlon RA. Conservation of the Notch signalling pathway in mammalian neurogenesis. *Development*. 1997; 124(6):1139–1148. [PubMed: 9102301]
71. Lutolf S, Radtke F, Aguet M, Suter U, Taylor V. Notch1 is required for neuronal and glial differentiation in the cerebellum. *Development*. 2002; 129(2):373–385. [PubMed: 11807030]
72. Yoon K, Nery S, Rutlin ML, Radtke F, Fishell G, Gaiano N. Fibroblast growth factor receptor signaling promotes radial glial identity and interacts with Notch1 signaling in telencephalic progenitors. *J Neurosci Off J Soc Neurosci*. 2004; 24(43):9497–9506.
73. Yang X, Klein R, Tian X, Cheng HT, Kopan R, Shen J. Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. *Dev Biol*. 2004; 269(1):81–94. [PubMed: 15081359]
74. Hitoshi S, Alexson T, Tropepe V, Donoviel D, Elia AJ, Nye JS, Conlon RA, Mak TW, Bernstein A, van der Kooy D. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. *Genes Dev*. 2002; 16(7):846–858. [PubMed: 11937492]
75. Breunig JJ, Silbereis J, Vaccarino FM, Sestan N, Rakic P. Notch regulates cell fate and dendrite morphology of newborn neurons in the postnatal dentate gyrus. *Proc Natl Acad Sci USA*. 2007; 104(51):20558–20563. [PubMed: 18077357]
76. Givogri MI, de Planell M, Galbiati F, Superchi D, Gritti A, Vescovi A, de Vellis J, Bongarzone ER. Notch signaling in astrocytes and neuroblasts of the adult subventricular zone in health and after cortical injury. *Dev Neurosci*. 2006; 28(1–2):81–91. [PubMed: 16508306]
77. Imayoshi I, Sakamoto M, Yamaguchi M, Mori K, Kageyama R. Essential roles of Notch signaling in maintenance of neural stem cells in developing and adult brains. *J Neurosci Off J Soc Neurosci*. 2010; 30(9):3489–3498.
78. Irvin DK, Nakano I, Paucar A, Kornblum HI. Patterns of Jagged1, Jagged2, Delta-like 1 and Delta-like 3 expression during late embryonic and postnatal brain development suggest multiple functional roles in progenitors and differentiated cells. *J Neurosci Res*. 2004; 75(3):330–343. [PubMed: 14743446]
79. Stump G, Durrer A, Klein AL, Lutolf S, Suter U, Taylor V. Notch1 and its ligands Delta-like and Jagged are expressed and active in distinct cell populations in the postnatal mouse brain. *Mech Dev*. 2002; 114(1–2):153–159. [PubMed: 12175503]
80. Ables JL, Decarolis NA, Johnson MA, Rivera PD, Gao Z, Cooper DC, Radtke F, Hsieh J, Eisch AJ. Notch1 is required for maintenance of the reservoir of adult hippocampal stem cells. *J Neurosci Off J Soc Neurosci*. 2010; 30(31):10484–10492.
81. Ehm O, Goritz C, Covic M, Schaffner I, Schwarz TJ, Karaca E, Kempkes B, Kremmer E, Pfrieger FW, Espinosa L, Bigas A, Giachino C, Taylor V, Frisen J, Lie DC. RBPJkappa-dependent signaling is essential for long-term maintenance of neural stem cells in the adult hippocampus. *J Neurosci Off J Soc Neurosci*. 2010; 30(41):13794–13807.

82. Borghese L, Dolezalova D, Opitz T, Haupt S, Leinhaas A, Steinfarz B, Koch P, Edenhofer F, Hampl A, Brustle O. Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. *Stem Cells*. 2010; 28(5):955–964. [PubMed: 20235098]
83. Basak O, Giachino C, Fiorini E, Macdonald HR, Taylor V. Neurogenic subventricular zone stem/progenitor cells are Notch1-dependent in their active but not quiescent state. *J Neurosci Off J Soc Neurosci*. 2012; 32(16):5654–5666.
84. Shimojo H, Ohtsuka T, Kageyama R. Oscillations in notch signaling regulate maintenance of neural progenitors. *Neuron*. 2008; 58(1):52–64. [PubMed: 18400163]
85. Shimojo H, Ohtsuka T, Kageyama R. Dynamic expression of notch signaling genes in neural stem/progenitor cells. *Front Neurosci*. 2011; 5:78. [PubMed: 21716644]
86. Nomura T, Goritz C, Catchpole T, Henkemeyer M, Frisen J. EphB signaling controls lineage plasticity of adult neural stem cell niche cells. *Cell Stem Cell*. 2010; 7(6):730–743. [PubMed: 21112567]
87. Aguirre A, Rubio ME, Gallo V. Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. *Nature*. 2010; 467(7313):323–327. [PubMed: 20844536]
88. Rash BG, Lim HD, Breunig JJ, Vaccarino FM. FGF signaling expands embryonic cortical surface area by regulating Notch-dependent neurogenesis. *J Neurosci Off J Soc Neurosci*. 2011; 31(43):15604–15617.
89. Agathocleous M, Iordanova I, Willardsen MI, Xue XY, Vetter ML, Harris WA, Moore KB. A directional Wnt/beta-catenin-Sox2-proneural pathway regulates the transition from proliferation to differentiation in the *Xenopus* retina. *Development*. 2009; 136(19):3289–3299. [PubMed: 19736324]
90. Amoyel M, Cheng YC, Jiang YJ, Wilkinson DG. Wnt1 regulates neurogenesis and mediates lateral inhibition of boundary cell specification in the zebrafish hindbrain. *Development*. 2005; 132(4):775–785. [PubMed: 15659486]
91. Hirsch C, Campano LM, Wohrle S, Hecht A. Canonical Wnt signaling transiently stimulates proliferation and enhances neurogenesis in neonatal neural progenitor cultures. *Exp Cell Res*. 2007; 313(3):572–587. [PubMed: 17198701]
92. Esteve P, Sandonis A, Cardozo M, Malapeira J, Ibanez C, Crespo I, Marcos S, Gonzalez-Garcia S, Toribio ML, Arribas J, Shimono A, Guerrero I, Bovolenta P. SFRPs act as negative modulators of ADAM10 to regulate retinal neurogenesis. *Nat Neurosci*. 2011; 14(5):562–569. [PubMed: 21478884]
93. Hashimoto M, Ishii K, Nakamura Y, Watabe K, Kohsaka S, Akazawa C. Neuroprotective effect of sonic hedgehog up-regulated in Schwann cells following sciatic nerve injury. *J Neurochem*. 2008; 107(4):918–927. [PubMed: 18786173]
94. Dave RK, Ellis T, Toumpas MC, Robson JP, Julian E, Adolphe C, Bartlett PF, Cooper HM, Reynolds BA, Wainwright BJ. Sonic hedgehog and notch signaling can cooperate to regulate neurogenic divisions of neocortical progenitors. *PLoS ONE*. 2011; 6(2):e14680. [PubMed: 21379383]
95. Borrell V, Cardenas A, Ciceri G, Galceran J, Flames N, Pla R, Nobrega-Pereira S, Garcia-Frigola C, Peregrin S, Zhao Z, Ma L, Tessier-Lavigne M, Marin O. Slit/Robo signaling modulates the proliferation of central nervous system progenitors. *Neuron*. 2012; 76(2):338–352. [PubMed: 23083737]
96. Ma S, Kwon HJ, Johng H, Zang K, Huang Z. Radial glial neural progenitors regulate nascent brain vascular network stabilization via inhibition of wnt signaling. *PLoS Biol*. 2013; 11(1):e1001469. [PubMed: 23349620]
97. Shen Q, Wang Y, Kokovay E, Lin G, Chuang SM, Goderie SK, Roysam B, Temple S. Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell–cell interactions. *Cell Stem Cell*. 2008; 3(3):289–300. [PubMed: 18786416]
98. Tavazoie M, Van der Veken L, Silva-Vargas V, Louissaint M, Colonna L, Zaidi B, Garcia-Verdugo JM, Doetsch F. A specialized vascular niche for adult neural stem cells. *Cell Stem Cell*. 2008; 3(3):279–288. [PubMed: 18786415]

99. High FA, Lu MM, Pear WS, Loomes KM, Kaestner KH, Epstein JA. Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. *Proc Natl Acad Sci USA*. 2008; 105(6):1955–1959. [PubMed: 18245384]
100. Popovici C, Isnardon D, Birnbaum D, Roubin R. *Caenorhabditis elegans* receptors related to mammalian vascular endothelial growth factor receptors are expressed in neural cells. *Neurosci Lett*. 2002; 329(1):116–120. [PubMed: 12161275]
101. Procko C, Lu Y, Shaham S. Glia delimit shape changes of sensory neuron receptive endings in *C. elegans*. *Development*. 2011; 138(7):1371–1381. [PubMed: 21350017]
102. Eichmann A, Thomas JL. Molecular parallels between neural and vascular development. *Cold Spring Harbor Perspect Med*. 2013; 3(1)
103. Eichmann A, Simons M. VEGF signaling inside vascular endothelial cells and beyond. *Curr Opin Cell Biol*. 2012; 24(2):188–193. [PubMed: 22366328]
104. Licht T, Goshen I, Avital A, Kreisel T, Zubedat S, Eavri R, Segal M, Yirmiya R, Keshet E. Reversible modulations of neuronal plasticity by VEGF. *Proc Natl Acad Sci USA*. 2011; 108(12):5081–5086. [PubMed: 21385942]
105. Raab S, Plate KH. Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. *Acta Neuropathol*. 2007; 113(6):607–626. [PubMed: 17492293]
106. Quaegebeur A, Lange C, Carmeliet P. The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. *Neuron*. 2011; 71(3):406–424. [PubMed: 21835339]
107. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. *Development*. 1992; 114(2):521–532. [PubMed: 1592003]
108. Hogan KA, Bautch VL. Blood vessel patterning at the embryonic midline. *Curr Top Dev Biol*. 2004; 62:55–85. [PubMed: 15522739]
109. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. *Proc Natl Acad Sci USA*. 2002; 99(18):11946–11950. [PubMed: 12181492]
110. Zhang H, Vutskits L, Pepper MS, Kiss JZ. VEGF is a chemoattractant for FGF-2-stimulated neural progenitors. *J Cell Biol*. 2003; 163(6):1375–1384. [PubMed: 14691144]
111. Sun J, Zhou W, Ma D, Yang Y. Endothelial cells promote neural stem cell proliferation and differentiation associated with VEGF activated Notch and Pten signaling. *Dev Dyn*. 2010; 239(9):2345–2353. [PubMed: 20730910]
112. Bellon A, Luchino J, Haigh K, Rougon G, Haigh J, Chauvet S, Mann F. VEGFR2 (KDR/Flk1) signaling mediates axon growth in response to semaphorin 3E in the developing brain. *Neuron*. 2010; 66(2):205–219. [PubMed: 20434998]
113. Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. *Physiol Rev*. 2009; 89(2):607–648. [PubMed: 19342615]
114. Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, Alitalo K. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. *Cancer Res*. 1992; 52(20):5738–5743. [PubMed: 1327515]
115. Wittko-Schneider IM, Schneider FT, Plate KH. Brain homeostasis: VEGF receptor 1 and 2—two unequal brothers in mind. *Cell Mol Life Sci*. 2013 (CMLS this issue).
116. Licht T, Keishet E. Delineating multiple functions of VEGF-A in the adult brain. *Cell Mol Life Sci*. 2013 (CMLS this issue).
117. Le Bras B, Barallobre MJ, Homman-Ludiyé J, Ny A, Wyns S, Tammela T, Haiko P, Karkkainen MJ, Yuan L, Muriel MP, Chatzopoulou E, Breant C, Zalc B, Carmeliet P, Alitalo K, Eichmann A, Thomas JL. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. *Nat Neurosci*. 2006; 9(3):340–348. [PubMed: 16462734]
118. Choi JS, Shin YJ, Lee JY, Yun H, Cha JH, Choi JY, Chun MH, Lee MY. Expression of vascular endothelial growth factor receptor-3 mRNA in the rat developing forebrain and retina. *J Comp Neurol*. 2010; 518(7):1064–1081. [PubMed: 20127810]

119. Hou Y, Choi JS, Shin YJ, Cha JH, Choi JY, Chun MH, Lee MY. Expression of vascular endothelial growth factor receptor-3 mRNA in the developing rat cerebellum. *Cell Mol Neurobiol.* 2011; 31(1):7–16. [PubMed: 21072582]
120. Hou Y, Shin YJ, Han EJ, Choi JS, Park JM, Cha JH, Choi JY, Lee MY. Distribution of vascular endothelial growth factor receptor-3/Flt4 mRNA in adult rat central nervous system. *J Chem Neuroanat.* 2011; 42(1):56–64. [PubMed: 21703344]
121. Shin YJ, Choi JS, Lee JY, Choi JY, Cha JH, Chun MH, Lee MY. Differential regulation of vascular endothelial growth factor-C and its receptor in the rat hippocampus following transient forebrain ischemia. *Acta Neuropathol.* 2008; 116(5):517–527. [PubMed: 18704465]
122. Calvo CF, Fontaine RH, Soueid J, Tammela T, Makinen T, Alfaro-Cervello C, Bonnaud F, Miguez A, Benhaim L, Xu Y, Barallobre MJ, Moutkine I, Lyytikka J, Tatlisumak T, Pytowski B, Zalc B, Richardson W, Kessaris N, Garcia-Verdugo JM, Alitalo K, Eichmann A, Thomas JL. Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis. *Genes Dev.* 2011; 25(8):831–844. [PubMed: 21498572]
123. Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ, Baldwin ME, Stacker SA, Achen MG, Alitalo K. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. *Mol Cell Biol.* 2008; 28(15):4843–4850. [PubMed: 18519586]
124. Samuels BA, Hen R. Neurogenesis and affective disorders. *Eur J Neurosci.* 2011; 33(6):1152–1159. [PubMed: 21395859]
125. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. *Behav Pharmacol.* 2007; 18(5–6):391–418. [PubMed: 17762509]
126. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. *Cell.* 2008; 132(4):645–660. [PubMed: 18295581]
127. Mauceri D, Freitag HE, Oliveira AM, Bengtson CP, Bading H. Nuclear calcium-VEGFD signaling controls maintenance of dendrite arborization necessary for memory formation. *Neuron.* 2011; 71(1):117–130. [PubMed: 21745642]
128. Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, Vincent P, Pumiglia K, Temple S. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. *Science.* 2004; 304(5675):1338–1340. [PubMed: 15060285]
129. Hashimoto T, Zhang XM, Chen BY, Yang XJ. VEGF activates divergent intracellular signaling components to regulate retinal progenitor cell proliferation and neuronal differentiation. *Development.* 2006; 133(11):2201–2210. [PubMed: 16672338]
130. De Schaepdrijver L, Simoons P, Lauwers H, De Geest JP. Retinal vascular patterns in domestic animals. *Res Vet Sci.* 1989; 47(1):34–42. [PubMed: 2772405]
131. Anthony TE, Mason HA, Gridley T, Fishell G, Heintz N. Brain lipid-binding protein is a direct target of Notch signaling in radial glial cells. *Genes Dev.* 2005; 19(9):1028–1033. [PubMed: 15879553]

Fig. 1.

Proposed models of Notch-VEGFRs interactions during angiogenesis and neurogenesis. **a** In ECs, VEGF-A-activated VEGFR-2 signaling up-regulates VEGFR-3, but only weakly induces Dll4 expression in tip cells, in vivo. Dll4 expression is regulated by either Notch signaling, extracellular matrix signals or other unknown regulators (*blue arrow*). Activation of Notch strongly down-regulates the level of VEGFR-3, but not VEGFR-2, in adjacent ECs. VEGFR-3 expression in ECs is thus regulated both by VEGFR-2 and Notch signaling, independently. Little to no Notch signaling in ECs leads to ligand-independent activation of VEGFR-3, which induces mispatterned angiogenic growth, even in the absence of VEGF-2 signaling (modified from Benedito et al. [12]). **b** In neural progenitor/stem cells, Delta-Notch cell membrane interactions induces cleavage and intra-nuclear translocation of NICD which activates HES1 transcription. It is not yet known whether Delta-presenting cells that stimulate Notch-presenting progenitor/stem cells are exclusively neural cells or if they also include ECs, both in the early embryonic neuroepithelium or in adult niches where ECs and some neural progenitor/stem cells establish direct cell membrane contacts. In embryonic retinal progenitors, VEGF-A-mediated activation of VEGFR-2 induces the MEK-ERK cascade and enhances HES1 activity, independently of Notch. Cell proliferation requires independent inputs from both MEK-ERK and HES1, whereas blocking of cell differentiation mainly involves HES1 activity. SHH signaling also activates HES1 (from [129]). In adult neural stem cells, VEGFR-3, rather than VEGFR-2, is expressed predominantly and may mediate Notch target activation following VEGF-C stimulation. *EC_S* EC stalk cell, *EC_T* EC tip cell

Fig. 2.

VEGF-A/C expression in the embryonic mouse brain cortex. **a** β -galactosidase reporter activity (X-gal staining) in the brain of a *Vegfc*^{lacZ/+} embryo at stage E13.5 reveals a high dorsal to low lateral gradient of *Vegfc* expression in the cortex of a whole-mount brain. *C* caudal, *R* rostral. **b** Immunolabeling of VEGF-C (green) in E13.5 brain shows expression in the dorsal cortex (*large arrows*) and the medial wall of telencephalon (*thin arrows*), especially at the ventricular surface, which correlates with the expression pattern of the *Vegfc*^{lacZ/+} brain (*white arrow*). While VEGF-A (red), on the same sections, is expressed by ECs (*arrowhead*) throughout the dorsal and ventral parts of the forebrain (*arrowhead*). Pictures at higher magnification display the vesicular pattern of expression for VEGF-C in neuroepithelial cells contrasting with the endothelial expression of VEGF-A. *dCX* dorsal cortex, *H* hem, *LGE* lateral ganglionic eminence, *LV* lateral ventricle. Scale bar 100 μ m

Fig. 3.

Synthetic scheme of VEGFR-3 expression by neural stem cells in the SVZ and SGZ of adult *Vegfr3::YFP* mice. **a** In the SVZ, VEGFR-3 is expressed by a subpopulation of astrocytes (**b**) and almost all NSCs (B1), but not in the majority of amplifying progenitors (**c**), neuroblasts (**a**). VEGF-C is produced by SVZ astrocytes among other cell types, promoting activation of VEGFR-3 expressing cells, including the stem cells, as evidenced by an increase in amplifying progenitor and neuroblast cell numbers following VEGF-C overexpression [122]. **b** In the SGZ, VEGFR-3 expression can be seen on immature cells including radial glia and horizontal cells, the region's stem cells, as well as the Mash1⁺ intermediate progenitors. It is not expressed by the less plastic neuronal precursors or the differentiated granule cells (Han, unpublished data)

Table 1

Microarray data showing upregulated transcripts of Notch and Notch signaling pathway genes in *Vegfr3::YFP⁺* compared to *Vegfr3::YFP⁻* cells

	Gene symbol	Ratio	<i>p</i> value
Notch signaling pathway genes	Notch 1	4.16	0.00133
	Hes5	17.26	0.00189
	Hey1	6.99	0.00189
	APP	3.5	0.00121
	Lfng	6.89	0.00106
	BLBP [131]	9.44	0.00304